Conduit Pharmaceuticals Inc. entered a $2 million agreement with Sarborg Limited on March 31, 2025, for data analysis of AstraZeneca assets, issuing 1,853,933 shares to cover fees. Additionally, 410,113 shares were issued for consulting services, totaling 9,549,800 shares outstanding.